Stock Region Penny Picks
Stock Region Penny Picks
Stock Region Penny Picks Newsletter - Monday, September 30th, 2024.
Stock Region Penny Picks Newsletter - Monday, September 30th, 2024
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational purposes only and should not be considered as financial advice. Please conduct your own research or consult a financial advisor before making any investment decisions.
$PRME - Prime Medicine
Prime Medicine has entered into a strategic research collaboration and license agreement with Bristol Myers Squibb. This collaboration focuses on developing and commercializing multiple Prime Edited ex vivo T-cell therapies, potentially paving the way for innovative treatments and boosting Prime Medicine's market position.
$BCRX - BioCryst Pharmaceuticals
BioCryst has been awarded a significant $69 million contract by the U.S. Government for RAPIVAB® (peramivir injection) to be included in the Strategic National Stockpile. This contract reinforces BioCryst's role in national health preparedness and could bolster revenue streams.
$TRAW - Traws Pharma
Traws Pharma announced encouraging topline results from its Phase 1 trials for Ratutrelvir, an oral Mpro inhibitor targeting COVID-19. Positive results in early trials may enhance investor confidence and advance Traws Pharma's position in the COVID-19 treatment landscape.
$EMKR - EMCORE Corporation
Mobix Labs has submitted an all-cash offer to acquire EMCORE Corporation. This acquisition proposal could lead to strategic growth opportunities and influence EMCORE's stock activity.
$NRBO - NeuroBo Pharmaceuticals
NeuroBo reports promising top-line data from Part 1 of its Phase 1 clinical trial for DA-1726, aimed at treating obesity. This development could signal potential breakthroughs in obesity treatment, attracting investor interest.
$HSDT - Helius Medical Technologies
Helius Medical Technologies announced positive preliminary results from the PoNSTEP study. These results could drive excitement around Helius' innovative treatments and influence market perceptions.
$CGC / $ACB - Canopy Growth and Aurora Cannabis
Both companies experienced increased trading volume following Vice President Kamala Harris's statement advocating for marijuana legalization. This political support might accelerate policy changes, affecting the cannabis industry positively.
$NITO - NITO N2OFF Inc.
NITO N2OFF Inc. and Solterra have unveiled new potential for capacity expansion in a Solar PV Project. This development could signify growth opportunities within the renewable energy sector.
$ZKIN - ZK International Group Co., Ltd.
ZK International announced a record revenue of $52.89 million for the first half of fiscal year 2024, marking a 6.5% increase. This financial performance highlights ZKIN's growth trajectory and may attract investor attention.
Disclaimer: This newsletter is for informational purposes only and should not be considered as financial advice. Please conduct your own research or consult a financial advisor before making any investment decisions.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net